

MEDIA RELEASE

Sulzer Management Ltd
Neuwiesenstrasse 15
8401 Winterthur
Switzerland
Phone +41 52 262 30 00
Fax +41 52 262 31 00

August 24, 2020

Sulzer to acquire Haselmeier

Medical Device portfolio to complement Sulzer's Applicator Systems business

Sulzer Ltd has agreed to acquire Swiss-German privately held drug delivery device developer and manufacturer Haselmeier for an enterprise value of EUR 100 million. Haselmeier is a leading, own-IP provider of drug delivery devices such as subcutaneous self-injection pens for use in fast growing indications such as reproductive health, growth disorders, osteoporosis and diabetes. With the acquisition of Haselmeier, Sulzer will complement its healthcare portfolio and leverage its APS expertise in precision injection molding to seize growth opportunities in the fast-growing drug delivery devices market.

Haselmeier employs 230 people and achieved sales of EUR 36m in 2019. The integration of the acquired business in Sulzer's APS division is expected to generate cost synergies through insourcing and leveraging the scale of the combined businesses. The transaction is expected to close on October 1, subject to customary closing conditions.

Girts Cimermans, President of Sulzer APS, commented: "We are excited to welcome the Haselmeier team into the APS family. Haselmeier has a successful track record of providing innovative drug delivery devices based on its proprietary IP business model. We believe that we will add to the success story by providing financial strength and precision injection molding capabilities, thereby accelerating the company's growth. Furthermore, combining our expertise in liquid mixing applications with Haselmeier's drug delivery competence, will benefit our pharmaceutical customers providing them with innovative and differentiated devices and services."

Sulzer is a global leader in fluid engineering. We specialize in pumping, agitation, mixing, separation and application technologies for fluids of all types. Our customers benefit from our commitment to innovation, performance and quality and from our responsive network of 180 world-class manufacturing facilities and service centers across the globe. Sulzer has been headquartered in Winterthur, Switzerland, since 1834. In 2019, our 16'500 employees delivered revenues of CHF3.7 billion. Our shares are traded on the SIX Swiss Exchange (SIX: SUN). www.sulzer.com

Haselmeier, with its parent company in Switzerland, is a leading provider of solutions for subcutaneous injection systems for the safe self-administration of liquid drugs. As a reliable development partner, Haselmeier offers customer-specific solutions from design and conception with prototype construction, engineering and product development to industrialization in modern production facilities. Additional services such as lifecycle management, pharmaceutical packaging, packaging design and regulatory support complement the range of services. The customized development is always based on patented proprietary platform technologies for injection devices.

Inquiries:

Media Relations: Domenico Truncellito, Head of External Communications
Phone +41 52 262 31 68, domenico.truncellito@sulzer.com

Investor Relations: Christoph Ladner, Head of Investor Relations
Phone +41 52 262 30 22, christoph.ladner@sulzer.com